Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib
Konrad H. Stopsack
Topics & Concepts
OlaparibMedicinePARP inhibitorProstate cancerHazard ratioOncologyCohortInternal medicineProstateCancerConfidence intervalPoly ADP ribose polymeraseGeneticsBiologyPolymeraseGenePARP inhibition in cancer therapyProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment